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Summary
 
Objective 
 
To assess the GH response to GHRH-arginine in appar-
ently healthy adults in relation to cardiovascular risk factors.
 
Design 
 
Cross-sectional.
 
Patients 
 
Eighty-six male and female volunteers aged 50–90.
 
Measurements 
 
GH peak response to GHRH-arginine and cardio-
vascular risk factors, including obesity, insulin resistance, low levels of
high density lipoprotein (HDL) cholesterol, elevated triglycerides, and
hypertension. The primary outcome measurement was GH response
to GHRH-arginine. The relationship between GH peak responses
and cardiovascular risk factors was determined after data collection.
 
Results 
 
GH peaks were highly variable, ranging from 2·3 to 185 
 
µ
 
g/l
(14% with GH peaks < 9 
 
µ
 
g/l). An increasing number of cardio-
vascular risk factors were associated with a lower mean GH peak
(
 
P <
 
 0·0001). By univariate analysis, fasting glucose, insulin, body
mass index (BMI), HDL cholesterol and triglycerides were signiﬁc-
antly associated with GH peak (all 
 
P
 
 < 0·0001). Multiple regression
analysis revealed that fasting glucose, fasting insulin, BMI, trigly-
cerides and sex accounted for 54% of GH peak variability. The role
of abdominal fat as it relates to GH peak was explored in a subset
of 45 subjects. Trunk fat and abdominal subregion fat measured by
dual energy X-ray absorptiometry (DXA) were inversely related to GH
peak (
 
P <
 
 0·008 and 0·001, respectively). Analysis of this subgroup
by multiple regression revealed that subregion abdominal fat became
the signiﬁcant obesity-related determinant of GH peak, but still
lagged behind fasting insulin and glucose.
 
Conclusions 
 
GH response to secretagogues was highly variable
in apparently healthy adults aged 50–90 years. Peak GH was
signiﬁcantly related to fasting glucose, insulin, BMI, HDL cholesterol,
triglycerides, trunk fat and abdominal subregion fat, with fasting
glucose ranking ﬁrst by multiple regression analysis. There was a
strong relationship between cardiovascular risk factors and low GH,
with individual risk factors being additive. Although these data do
not differentiate between low GH being a cause or an effect of these
cardiovascular risk factors, they indicate that the relationship
between low GH and increased cardiovascular risk may be physio-
logically important in the absence of pituitary disease.
(Received 10 January 2006; returned for revision 10 February 2006; 
 
ﬁnally revised 4 April 2006; accepted 5 April 2006)
 
Introduction
 
Cardiovascular risk factors such as obesity, insulin resistance and
dyslipidaemia cause major morbidity and mortality in the adult
population.
 
1,2
 
 A similar association has been established in children and
adults with GH deﬁciency (GHD) due to pituitary or hypothalamic
disease, imparting increased morbidity and mortality largely due
to cerebrovascular and cardiovascular disease.
 
3–7
 
 Treatment with GH
has been demonstrated to improve cardiovascular risk proﬁles in
subjects with GHD due to pituitary or hypothalamic disease.
Over the years, investigators have sought to establish the deter-
minants of GH secretion in normal adults. Many relationships have
been consistently demonstrated: lower 24 h GH secretion is associated
with advancing age,
 
8–11
 
 male gender,
 
12
 
 obesity,
 
13
 
 total body fat
 
14–19
 
and abdominal adiposity.
 
20–25
 
 Similarly, GH responses to a variety
of pharmacological stimuli have shown an inverse relationship to
body mass index (BMI)
 
13,25–32
 
 and abdominal adiposity.
 
33,34
 
 Some of
these studies have also demonstrated relationships between GH
secretory patterns and fasting insulin
 
24
 
 and serum lipids.
 
23
 
While other studies have demonstrated relationships between GH
dynamics and various cardiovascular risk factors in normal adults,
GH response to secretagogues has not been assessed in a self-selected
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adult population of active, relatively healthy older individuals, nor has
a relationship between GH peak and a clustering of cardiovascular
risk factors been demonstrated. To determine normative data on GH
response to GHRH-arginine, we studied a group of 86 apparently
healthy adult male and female volunteers between the ages of 50 and
90. These responses were later analysed in relation to the presence
or absence of cardiovascular risk factors.
 
Methods
 
Study subjects
 
To  assess the variability of GH responses to GH secretagogues, we
recruited a group of 86 normal volunteers between the ages of 50
and 90. This was initially done in collaboration with the Aging and
Dementia Center at NYU and subsequently through town meetings,
local advertisements and word of mouth. Volunteers were excluded
from participating if they were nonambulatory, had a history of
nonbasal cell malignancy, chronic renal or liver disease, cognitive or
psychological dysfunction, were taking antipsychotic medications,
or if they had been treated with GH during the 6 months prior to
participation. None of the subjects, including those with BMI < 25,
had undergone any recent signiﬁcant weight changes. All subjects
were screened for the presence of pituitary dysfunction by hormonal
analysis. Subjects with pituitary abnormalities were excluded from
the study.
 
Study protocol
 
The NYU Institutional Board of Research Associates approved the
protocol. After informed consent, each participant had a complete
history and physical examination, electrocardiogram, fasting screening
laboratory analysis, and endocrine function testing.
Two weeks after the initial visit, subjects underwent a repeat
fasting measurement of IGF-I and GH stimulation testing with the
combination of GHRH (1 
 
µ
 
g/kg) and arginine (30 g in 300 ml over
30 min) infused intravenously. Samples were drawn through an
indwelling catheter every 30 min from 
 
−
 
30 min to 120 min, with
subjects supine.
Cardiovascular risk factors were assessed in each individual and
subjects were identiﬁed as having or not having abnormalities of ﬁve
different categories of cardiovascular risk: increased BMI (
 
≥
 
 27·5),
low HDL [< 1·0 mmol/l (< 40 mg/dl) for males and < 1·3 mmol/l
(<  50  mg/dl) for females], elevated triglycerides [
 
≥
 
 1·7 mmol/l
(
 
≥ 
 
150 mg/dl) or use of nonstatin lipid therapy], hypertension
(history of hypertension or blood pressure 
 
≥
 
 130/85 mmHg), and
insulin resistance [history of type 2 diabetes mellitus or fasting
glucose > 6·1 mmol/l (> 110 mg/dl)]. After identifying abnormalities
of individual cardiovascular risk, the subjects were divided into
two groups: those with two or fewer abnormal cardiovascular risk
categories (group A) and those with three or more cardiovascular
risk categories (group B).
All tests and measurements were carried out on the 86 volunteers
except dual energy X-ray absorptiometry (DXA) scans, which were
performed on a subset of 45 of the initial 86 volunteers. All subjects
available and willing to undergo DXA scanning were included.
 
Laboratory studies
 
Screening laboratory tests including complete blood count, hepatic
panel, basic metabolic panel, serum cortisol, lipid proﬁle and urinalysis
were undertaken by standard techniques at the Bellevue Hospital Center
Laboratory. Endocrine function testing, including TSH, free thyroxine,
FSH, LH, oestradiol, PRL and total testosterone, was undertaken by
Quest Diagnostics (Teterboro, NJ, USA) using standard techniques.
GH and IGF-I were measured by Quest Diagnostics Nichols Institute
(San Juan Capistrano, CA, USA) using the Nichols Advantage® HGH
and IGF-I assays. The GH assay is a two-site chemiluminescence
immunoassay with a sensitivity of 0·1 
 
µ
 
g/l. The intra-assay coefﬁcients
of variation (CVs) were 4·2%, 4·8% and 8% for detected GH levels
at 0·8 
 
µ
 
g/l, 2·42 
 
µ
 
g/l and 23·6 
 
µ
 
g/l, respectively. The interassay
CVs were 4·1%, 5·8% and 12·1% with corresponding GH levels of
0·92 
 
µ
 
g/l, 2·40 
 
µ
 
g/l and 23·7 
 
µ
 
g/l. Methods for the chemiluminescent
assay for IGF-I have been reported previously.
 
35
 
 Total serum insulin
was measured by radioimmunoassay (RIA) after acid treatment
and polyethylene glycol (PEG) precipitation (Quest Diagnostics
Nichols Institute).
The homeostatic model assessment of insulin resistance (HOMA-IR)
was calculated using fasting insulin levels (mU/l) and simultaneous
fasting serum glucose (mmol/l) using the following equation: HOMA-
IR = (fasting insulin 
 
× 
 
fasting glucose)/22·5.
 
36
 
Body composition measurement
 
Forty-ﬁve subjects completed DXA scanning. Whole-body DXA
measurements were obtained using the Hologic QDR-1000/W
(Waltham, MA, USA) with standard protocol. The same experienced
technician performed all of the scans. Although scans were obtained
2 years after the initial workup, the weights obtained at the time of
DXA scanning were highly correlated with those obtained at baseline
(
 
r
 
 = 0·973, 
 
P
 
 < 0·0001). We analysed the QDR-1000/W results for the
whole body as well as for regions of interest, including the trunk, arms
and legs. During a separate analysis, a manually deﬁned abdominal
subregion was examined by DXA.
 
37
 
 Measurements of total body fat,
trunk fat and abdominal subregion fat were used for this analysis.
Total body DXA has a CV of 2–3% for total body fat mass and
1–2% for fat free mass.
 
38,39
 
 Measures of trunk fat and abdominal fat
by DXA have been found to correlate signiﬁcantly with measures
of total abdominal fat and abdominal visceral fat by computed
tomography (CT).
 
37,40
 
 Trunk fat and abdominal subregion fat were
corrected for total body fat and expressed as the ratio of trunk or
subregion to total body fat.
 
41
 
Statistics
 
The ﬁrst objective of the statistical analysis was to determine which
variables, alone or in combination, were associated with GH peak.
Prior to performing a multiple regression analysis, candidate
predictor variables were identiﬁed by using simple correlation analysis
for each predictor variable with the log GH peak. Those variables with
correlations signiﬁcant at 
 
P
 
 < 0·05 (BMI, HDL cholesterol, triglyc-
erides, total/HDL cholesterol ratio, fasting glucose, fasting insulin
and sex) were entered into the regression model. Multiple regression 
GH and cardiovascular risk factors
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analysis using a backward elimination method was applied to the
data with 
 
P
 
 < 0·10 being the criterion for a variable to remain in the
model. BMI was used as the preferred method over weight as a measure
of obesity in the regression model. A second multiple regression
analysis was performed on the subset of 45 subjects who returned
for whole-body DXA scan. Methods for this multiple regression
model were identical to those described above. Those variables with
correlations signiﬁcant at 
 
P
 
 < 0·05 (BMI, triglycerides, HDL choles-
terol, total/HDL cholesterol ratio, fasting glucose, fasting insulin, and
corrected trunk fat and corrected abdominal subregion fat) were
entered into this regression model. The percentage of contribution
to the variance in GH peak for each individual parameter was deter-
mined by using the square of the Pearson correlation coefﬁcient (
 
R
 
2
 
).
Standardized regression coefﬁcients were used to rank the variables
that remained in the ﬁnal regression models. Comparison of means
was performed using Student’s 
 
t
 
-test, unless noted otherwise. One-way
analysis of variance (
 

 
) was used to compare mean log GH peak
values according to the number of cardiovascular risk parameters
within subjects. Analyses were performed using SAS version 9·1 (SAS
Institute, Cary, NC, USA). All analyses involving GH peak were
performed on base 10 log transformed GH peak responses to GHRH-
arginine secretagogue testing because the log transform yielded
nearly gaussian residuals in the regression model. However, for
simplicity of presentation, descriptive statistics regarding GH peak
are presented in original untransformed units, and have been plotted
using a logarithmic scale.
 
Results
 
Demographics
 
Demographic data are presented in Table 1. There were 57 women
and 29 men: 82·5% of the subjects were non-Hispanic Caucasian,
12·8% Hispanic Caucasian, 3·5% Asian, and 1·2% Black. Mean age
was 65·4 
 
±
 
 9·1 years [all data are presented as mean 
 
±
 
 standard deviation
(SD) unless noted otherwise]. BMI ranged from 19·3 to 48·5. Thirty-
ﬁve per cent of subjects had BMI < 25, 41% 
 
≥
 
 25 and < 30, 21% 
 
≥
 
 30
and < 40, and 4% 
 
≥
 
 40. Mean IGF-I for the sample was 122·8 
 
±
 
52·2 
 
µ
 
g/l at visit 1 and 119·4 
 
±
 
 52·6 
 
µ
 
g/l at visit 2 (1 
 
µ
 
g/l = 1 ng/ml).
The variability and reliability of a single IGF-I measurement in these
volunteers has been reported previously.
 
35
 
Response of GH to GHRH-arginine stimulation
 
GH peak varied from 2·3 to 185 
 
µ
 
g/l (mean 34·8 
 
±
 
 35·9 
 
µ
 
g/l; median
23·2 
 
µ
 
g/l; Fig. 1). Five volunteers had values consistent with a rigorous
deﬁnition of GHD (peak GH < 5·0 
 
µ
 
g/l).
 
42
 
 An additional seven
individuals had GH peaks between 5·0 and 8·2 
 
µ
 
g/l, values consistent
with GHD by other criteria (GH 
 
≤
 
 9·0 
 
µ
 
g/l).
 
43,44
 
  Twenty-nine
subjects had GH peak responses less than 16 
 
µ
 
g/l, the cutoff point
suggested by Ghigo 
 
et al.
 
 for normal subjects.
 
45
 
 Thus, while not
diagnostic of GHD, 12 subjects (14%) of our sample population had
GH peaks that would be consistent with GHD (< 9 
 
µ
 
g/l).
 
43
 
GH peaks were above 107·0 
 
µ
 
g/l (> 2 SD above mean peak) in ﬁve
volunteers. All were female and none had elevated IGF-I levels or
clinical features suggestive of acromegaly. All were postmenopausal
and four of the ﬁve were taking hormone replacement therapy. One
subject was taking a daily oral conjugated oestrogen–progesterone
combination tablet, one a weekly oestradiol patch, one a biweekly
combination oestradiol–norethindrone acetate patch, and one was
taking oral medroxyprogesterone and using topical oestrogen cream.
Mean BMI was 21·2 
 
±
 
 1·8 (all < 25) and mean height was 155 
 
±
 
6·3 cm (range 148–160 cm). We did not consider them GH resistant
because nonstimulated GH levels were not elevated (GH t-30 and
GH t0 means were 2·76 
 
±
 
 2·8 and 0·98 
 
±
 
 0·932 
 
µ
 
g/l, respectively).
One female subject had a GH peak of 3·5 
 
µ
 
g/l and a conﬁrmed,
elevated IGF-I of 351 
 
µ
 
g/l. She was fully evaluated and found to have
a normal pituitary magnetic resonance imaging (MRI), normal GH
suppression in response to oral glucose and no physical signs or
symptoms consistent with acromegaly. No explanation for this disparity
between GH results and IGF-I was found. Despite her abnormal
results, she met inclusion and exclusion criteria and was therefore
included in the analyses.
Table 1. Demographics for the whole group and the subset that had 
subsequent DXA scans
Whole group 
(n = 86)
DXA subset 
(n = 45) Signiﬁcance
Gender 57F/29M 32F/13M ns*
Age (years) 65·4 ± 9·2 64·0 ± 10·1 ns*
BMI (kg/m
2) 27·6 ± 5·6 27·0 ± 5·4 ns*
Height (cm) 163·9 ± 9·8 164·3 ± 9·3 ns*
Weight (kg) 74·5 ± 17·7 73·2 ± 17·7 ns*
Fasting glucose (mmol/l) 5·4 ± 1·2 5·2 ± 0·6 ns*
Systolic BP (mmHg) 129·3 ± 17·8 128·0 ± 17·8 ns*
Diastolic BP (mmHg) 73·6 ± 10·6 73·1 ± 10·1 ns*
Total cholesterol (mmol/l) 5·3 ± 1·2 5·6 ± 1·1 ns*
HDL cholesterol (mmol/l) 1·6 ± 0·5 1·6 ± 0·5 ns*
LDL cholesterol (mmol/l) 3·2 ± 1·0 3·4 ± 0·8 ns*
Triglycerides (mmol/l) 1·5 ± 0·8 1·5 ± 1·0 ns*
HOMA-IR 3·6 ± 2·6 3·0 ± 1·5 ns*
GH peak (µg/l)
Arithmetic mean (± SD) 34·8 ± 35·9 39·7 ± 41·5 ns†
Median 23·2 31·3
IGF-I (µg/l)
Visit 1 122·8 ± 52·2 129·1 ± 59·5 ns*
Visit 2 119·4 ± 52·6 126·9 ± 62·1 ns*
Coronary artery disease (n)4 3 ns‡
Diabetes mellitus type 2 (n)7 2 ns‡
Hyperlipidaemia (n)2 9 1 5 ns‡
Hypertension (n)2 41 3 ns‡
Lipid therapy (n)1 7 8 ns‡
Oral diabetes therapy (n)5 1 ns‡
Hypertension therapy (n)2 2 1 1 ns‡
BMI ≥ 27·5 (n, %) 42 (49) 19 (42) ns§
DXA, dual energy X-ray absorptiometry; BP, blood pressure; HDL, high 
density lipoprotein; LDL, low density lipoprotein; BMI, body mass index.
All data presented as mean ± standard deviation unless noted otherwise.
ns = P > 0·05 by *Student’s t-test, †Student’s t-test using mean log GH, 
‡Fisher’s exact test, and §χ
2.
18 mg/dl glucose = 1 mmol/l; 38·67 mg/dl cholesterol = 1 mmol/l; 88·57 mg/
dl triglycerides = 1 mmol/l.172 J. D. Carmichael et al.
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Relationship of GH peak to age and gender
The relationship between GH peak responses to GHRH-arginine and
age was not signiﬁcant. As reported previously,
12 the mean GH peak
was higher in women than in men (41·7 ± 41·2 vs. 21·2 ± 14·8 µg/l,
respectively; P < 0·01). This difference was not attributable to BMI,
which was not signiﬁcantly different between men and women.
Three female subjects were not postmenopausal and 13 postmeno-
pausal women were taking exogenous oestrogen. When the mean of
log GH peak of postmenopausal women not on oestrogen (n = 41)
was compared to that of men (n = 29), the difference was still
signiﬁcant (P < 0·002). For male subjects, there was a signiﬁcant direct
relationship between log GH peak and testosterone levels (r = 0·562,
P  <  0·002). For male or female subjects, the correlation between
log GH peak and oestrogen levels was not signiﬁcant.
Relationship of individual cardiovascular risk factors 
to GH peak
There were signiﬁcant correlations between log transformed GH
peak and BMI, HDL, triglycerides, cholesterol/HDL ratio, fasting
glucose, fasting insulin, and HOMA-IR (Table 2).
Studies relating to clustering of cardiovascular risk factors
Subjects were identiﬁed as having or not having an abnormality of
the ﬁve following cardiovascular risk factors: obesity, hypertension,
low HDL, high triglycerides, and insulin resistance. Twenty-two
subjects had no abnormal risk factors, 23 had one of ﬁve categories,
22 had two of ﬁve categories, 13 had three of ﬁve, and six had four
of ﬁve categories. None had all ﬁve categories. Subjects were then
grouped according to the number of abnormal categories: group A
(two or fewer categories) and group B (three or more abnormal
cardiovascular risk factors). Nineteen of the 86 subjects (22%) were in
group B and 67 of 86 (78%) were in group A. Mean log GH peak was
signiﬁcantly lower in subjects in group B than in those in group A
(P < 0·0001; Fig. 2a). When subjects were assessed according to the
number of cardiovascular risk factors, one-way   of mean
log GH peaks according to the number of cardiovascular risk
Fig. 1 Variability of peak GH responses to 
GHRH-arginine. Individual peak GH responses 
in 86 volunteers between 50 and 90 years of age.
Table 2. Correlation between log GH peak and parameters of cardiovascular 
risk
Parameter
Whole group 
(n = 86)
BMI ≥ 27·5 
(n = 42)
DXA subset 
(n = 45) 
rP rP rP
BMI –0·51 < 0·0001 –0·18 < 0·253 –0·57 < 0·0001
HDL cholesterol 0·43 < 0·0001 0·22 < 0·168 0·35 < 0·02
Triglycerides –0·41 < 0·0001 –0·21 < 0·192 –0·39 < 0·008
Fasting glucose –0·55 < 0·0001 –0·50 < 0·001 –0·61 < 0·0001
Systolic BP –0·16 < 0·152 0·12 < 0·433 –0·07 < 0·649
Diastolic BP –0·14 < 0·20 –0·08 < 0·638 –0·05 < 0·736
Insulin –0·52 < 0·0001 –0·41 < 0·007 –0·65 < 0·0001
HOMA-IR –0·52 < 0·0001 –0·43 < 0·005 –0·69 < 0·0001
Chol/HDL –0·44 < 0·0001 –0·18 < 0·268 –0·45 < 0·002
Total cholesterol 0·06 < 0·58 0·15 < 0·329 0·01 < 0·976
LDL cholesterol –0·01 < 0·96 0·16 < 0·317 –0·03 < 0·847
BMI, body mass index; DXA, dual energy X-ray absorptiometry; HDL, high 
density lipoprotein; BP, blood pressure; HOMA-IR, homeostasis model 
assessment – insulin resistance; Chol/HDL, total cholesterol/high density 
lipoprotein cholesterol; LDL, low density lipoprotein.
Pearson correlation coefﬁcients between parameters and log GH peak for the 
whole group (n = 86), a subgroup of 42 subjects whose BMI was ≥ 27·5, and 
a subgroup of 45 subjects having had body composition measurements by 
DXA. Signiﬁcant relationships are shown in bold.GH and cardiovascular risk factors 173
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categories (0, 1, 2, 3 and 4 risk factors) revealed a signiﬁcant differ-
ence between groups. An increasing number of risk factor categories
was associated with lower GH peaks (P < 0·0001; Fig. 2b).
Multiple regression analysis
Candidate variables for multiple regression analysis were determined
based on signiﬁcance of factors related to GH peak determined by
univariate analysis as shown in Table 2. Fasting glucose, fasting
insulin, BMI, triglycerides and sex explained 54% (R
2 = 0·5379) of the
variation in GH peak (Table 3). Based on the standardized regression
coefﬁcients, the relative importance of the ﬁve predictor variables
from highest to lowest was: fasting glucose, BMI, triglycerides, sex
and fasting insulin. Low GH peak was associated with high fasting
glucose levels, high BMI, high triglycerides, male gender and high
fasting insulin levels. Although HOMA-IR was highly correlated with
GH peak, due to multicollinearity among HOMA-IR, insulin and
glucose (because of the dependence of HOMA-IR on the other two
variables), HOMA-IR was not used in the multiple regression analysis.
Relationship of BMI to GH peak
When the group as a whole was divided into subgroups according
to BMI (≥ 27·5 and < 27·5), the relationship between BMI and GH
peak was maintained in the lower BMI group but not in subjects with
BMI ≥ 27·5 (Fig. 3a). By contrast, the relationships between GH peak
and fasting glucose, fasting insulin and HOMA were maintained in both
groups (Table 2, Fig. 3b, data not shown for fasting insulin and HOMA).
In the subgroup of subjects with BMI ≥ 27·5, variability in GH
peak was still present. Mean log GH peak for subjects in group B
(mean 12·7 ± 8·9 µg/l, median 11·2 µg/l, n = 18) was lower than for
those in group A (mean 23·6 ± 14·4 µg/l, median 20·7 µg/l, n = 24)
(P < 0·004). There was no statistically signiﬁcant difference in BMI
between subjects in group B vs. group A (30·9 ± 4·0 vs. 32·4 ± 5·7 kg/m
2,
respectively; P < 0·33).
Assessment of abdominal adiposity
We measured total, trunk and abdominal subregion fat using whole-body
DXA in a subset of 45 of the 86 original subjects. Measurements of
abdominal subregion fat are highly correlated with measures of visceral
adiposity by CT scan.
37,40 There were no signiﬁcant demographic dif-
ferences between the whole group and the DXA participant group
(Table 1), nor did they differ regarding their relationships between GH
peak and cardiovascular risk factors (Table 2). In fact, weights obtained
at the time of DXA scanning were highly correlated with those obtained
at baseline (r = 0·973, P < 0·0001). Total body fat was signiﬁcantly
correlated with both trunk fat (r = 0·887, P < 0·0001) and abdominal
subregion fat (r = 0·837, P < 0·0001). Total body fat was not signiﬁcantly
related to GH peak. However, corrected trunk fat (r = –0·606, P < 0·0001)
and corrected abdominal subregion fat (r = –0·612, P < 0·0001) were
associated with the log of GH peak. In each case, total body fat, trunk
and abdominal subregion fat correlated with BMI (P < 0·0001).
Subgroup multiple regression analysis
Multiple regression analysis was performed on the subgroup of 45 sub-
jects who had body composition analysis by DXA. Candidate predictor
Fig. 2 Relationship of GH peak to cardiovascular risk factors. (a) Mean log 
GH peak was signiﬁcantly lower in 19 volunteers with three or more 
cardiovascular risk factors compared to 67 with two or fewer cardiovascular 
risk factors. (b) GH peak in 86 subjects divided according to number of 
cardiovascular risk factors [0 (n = 22), 1 (n = 23), 2 (n = 22), 3 (n = 13), and 
4 (n = 6)]. Median arithmetic values for GH peak are displayed. Statistics 
performed by Student’s t-test (a) and one-way analysis of variance () 
(b). (1 ng/ml GH = 1 µg/l.)
Table 3. Results of multiple regression analysis
Variable Coefﬁcient
Standardized 
coefﬁcient Signiﬁcance
Intercept 2·6129 0 < 0·0001
Fasting glucose −0·0053 −0·2812 0·0030
BMI −0·0190 −0·2782 0·0032
Triglycerides −0·0019 −0·2654 0·0013
Sex 0·1770 0·2112 0·0134
Fasting insulin −0·0096 −0·1636 0·0929
Analysis of the whole group (n = 86) showed that fasting glucose, body mass 
index (BMI), triglycerides, sex and fasting insulin accounted for 54% of GH 
variance.174 J. D. Carmichael et al.
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variables were again determined based on the signiﬁcance of factors
related to the GH peak determined by univariate analysis as shown
in Table 2. Total fasting insulin, fasting glucose, HDL and the corrected
subregion fat explained 69% (R
2 = 0·69) of the variation in GH peak.
Based on the standardized regression coefﬁcients, the relative importance
of the predictor variables from highest to lowest was: fasting insulin,
fasting glucose, HDL cholesterol and corrected subregion fat. Low GH
peak was associated with high fasting insulin levels, high fasting glucose,
low HDL and a high ratio of abdominal subregion fat to total body fat.
Discussion
This paper presents the results of GH responses to GHRH-arginine
in a group of 86 normal volunteers between the ages of 50 and 90.
The study subjects were self-selected and were included on the basis
of age, apparent health, and absence of pituitary disease. Their demo-
graphic proﬁle with regard to obesity
46 is comparable to that of the
US population, suggesting that these results may be generalizable.
We  noted a wide variation in the peak GH responses, which
ranged from 2·3 to 185 µg/l. We found that 14% of the sample had
GH peaks of 8·2 µg/l or below and 6% had values that were greater
than 2 SD above the mean.
Our approach differs from previous studies assessing GH response
to GHRH-arginine in a number of ways. Other studies selected their
subjects based on the presence or absence of obesity,
26–28,45 focused on
younger age
47 or as matched controls for the subjects with pituitary
disease.
26,42 It was concluded from these studies of selected subjects, as
well as others measuring 24-h integrated GH concentration,
14–24,48–50
that GH was low in obese subjects. Many studies demonstrated low
GH concentrations or peaks in obese as compared to nonobese
subjects.
14,25,32,48 The observation that weight loss was associated with
an increase in GH secretion adds support to the idea that obesity
suppresses GH secretion.
15,32,51 Although we also noted a signiﬁcant
correlation between BMI and log GH peak in the sample as a whole,
we were surprised to ﬁnd that the relationship between the two lost
signiﬁcance when subjects whose BMI was ≥ 27·5 were considered
separately (r = –0·181,  P  <  0·253). The relationship between GH
peak and BMI was maintained and strongly correlated in subjects
with BMI below 27·5 (P < 0·0001; see Fig. 3a). Thus, we could
conclude that leanness is a more important determinant of GH
responsiveness than obesity is to impaired GH response. While other
studies have not reported similar ﬁndings, Bonert et al. and Corneli
et al. presented graphs on GH peak according to BMI that look very
similar to ours.
26,28 It is possible that GH peak does not go down
further once a threshold for obesity is reached.
More recent studies comparing abdominal fat to GH dynamics by
DXA,
21 including the present study, or abdominal visceral fat by CT
or MRI
22–24,33,34 show a high degree of correlation between lower GH
and higher abdominal fat. In this study, when we looked at abdominal
fat in a subset of the large sample, abdominal subregion fat was a
more signiﬁcant predictor of low peak GH than high BMI.
Although the GHRH-arginine stimulation test is a valid measure of GH
secretion in patients with pituitary disease, and does discriminate
between GH-deﬁcient and GH-sufﬁcient individuals, the test
does not necessarily reﬂect physiological GH secretion in subjects
without pituitary disease. We observed no relationship between age
and GH peak in response to GHRH-arginine stimulation. Other
investigators have also noted the lack of relationship between age and
GH peak with the use of this secretagogue test.
45,52,53 The decline in
GH secretion has been shown primarily with 24-h assessments
of GH secretion, which may more accurately reﬂect physiological
secretion. It is also important to note that the decline in GH secretion
is not linear, with more sizeable reduction in secretion noted in the
fourth and ﬁfth decades of life.
50 We observed an inverse relationship
between GH peak and BMI, trunk fat and abdominal fat, independent
of age in subjects between the ages of 50 and 90. While the GHRH-
arginine test may demonstrate a preservation of GH secretory potential
with age, it is still subject to the inﬂuences of BMI.
The inverse relationship between measures of insulin resistance
and GH response was highly signiﬁcant in univariate analyses and
Fig. 3 (a) Relationship of body mass index (BMI in kg/m
2) to GH peak. 
Subjects with BMI < 27·5 are represented by ﬁlled circles ( ) and those with 
BMI ≥ 27·5 by open squares ( ). Separate regression lines were drawn for 
subjects with BMI < 27·5 (solid line) and those with BMI ≥ 27·5 (dashed 
line). Relationship between GH and BMI was signiﬁcant when BMI was 
< 27·5 (r = –0·516, P < 0·0001) but was lost when only those with BMI ≥ 27·5 
were considered (r = –0·181, P < 0·253). (b) Relationship of fasting glucose 
to GH peak according to BMI. For BMI < 27·5 the relationship between GH 
and fasting glucose was signiﬁcant (r = –0·580, P < 0·0001), as was the 
relationship between GH and glucose in BMI ≥ 27·5 (r = –0·495, P < 0·001). 
(1 ng/ml GH = 1 µg/l.)GH and cardiovascular risk factors 175
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also ranked highest among signiﬁcant contributors in the multiple
regression analyses. In fact, when assessed according to BMI sub-
group, the relationship was signiﬁcant in subjects with both low and
high BMIs. As far as we know, only in the study by Clasey et al. did
fasting insulin play so important a role in GH secretory dynamics.
24
Some have suggested a direct inhibitory effect of insulin on GH
secretion.
54,55
We also found a direct correlation between low GH peak and HDL
cholesterol and an inverse relationship with triglycerides and the
cholesterol/HDL ratio. This conﬁrms the observation by O’Connor
et al. who studied 24-h GH secretory patterns as they relate to lipids
and abdominal fat in a similar group of subjects.
23 They did not,
however, assess measures of insulin resistance.
We found no correlation between the log of peak GH and low
density lipoprotein (LDL) or total cholesterol, as well as no correlation
between GH and measures of blood pressure. It should be noted that
these parameters were evaluated in the presence of LDL targeted lipid
therapy and hypertension therapy in many subjects, making the
interpretation of direct correlations between GH and blood pressure,
LDL or total cholesterol less reliable.
Although there are many common features between subjects with
GHD due to pituitary disease and subjects with a clustering of
cardiovascular risk factors in the absence of pituitary disease, it is
not clear whether the low GH associated with these cardiovascular
risk factors is cause or effect. Low GH in the setting of obesity has
been shown to be reversed with weight reduction, implying that it
is obesity that causes the low GH.
15,32,51 By contrast, the observation
that subjects with GHD due to pituitary or hypothalamic disease
develop obesity and its metabolic consequences suggests that
GH plays a physiological role in the development of obesity and its
cardiovascular complications.
3,4 This distinction is important in our
understanding of the role of GH in the development and maintenance
of cardiovascular risk factors, and may have therapeutic implications.
A future study establishing the prevalence of low GH, determining the
relationship of low GH to the various cardiovascular risk factors, and
examining the efﬁcacy of low-dose treatment with GH on improving
cardiovascular risk factors may show the efﬁcacy of GH treatment
on improving these risk factors, but would still not prove cause or
effect. One possible way of determining this distinction is by assessing
subjects’ baseline GH status and following these subjects in a longi-
tudinal trial, observing cardiovascular outcome over many years.
While previous studies have demonstrated a relationship between
GH and individual cardiovascular risk factors in otherwise normal
adults, our study is the ﬁrst to show that peak GH is inversely
proportional to the number of major cardiovascular risk categories.
By studying a cohort of individuals largely representative of middle-
class Caucasian New Yorkers, and assessing cardiovascular risk
factors as part of the study rather than as inclusion criteria, we were
able to examine differences between GH dynamics in those with
cardiovascular risk factors compared to those without. The striking
correlation of low GH to individual cardiovascular risk factors suggests
an important role for GH in the clustering of these risk factors,
whether or not the relationship is a causative one. Analogous to the
gradual acceptance of a wide variety of what are now considered
traditional cardiovascular risk factors, perhaps it is time to consider
low GH as an independent marker for cardiovascular disease.
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